Mosunetuzumab + Pirtobrutinib for Waldenstrom's Macroglobulinemia

(MPOWER Trial)

This trial tests the safety and effectiveness of two study drugs, mosunetuzumab and pirtobrutinib, in treating Waldenstrom's Macroglobulinemia, a type of blood cancer. The researchers aim to determine if this combination benefits individuals whose cancer has returned or resisted previous treatments. Participants will explore two different dosing strategies to identify the most effective approach. Those diagnosed with Waldenstrom's Macroglobulinemia and who have undergone at least one prior treatment may be suitable candidates. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial protocol does not specify if you need to stop taking your current medications. However, certain medications like systemic immunosuppressive drugs and recent anticancer therapies are not allowed. It's best to discuss your specific medications with the trial team.

Research has shown that both mosunetuzumab and pirtobrutinib are generally safe for patients. Studies have found that mosunetuzumab, whether used alone or with other medications, is usually well-tolerated. Common side effects include fatigue and mild injection site reactions, which are typically manageable and temporary.

Pirtobrutinib has been studied for several years and received FDA approval for treating mantle cell lymphoma, indicating a known safety profile. In a 5-year follow-up study, pirtobrutinib was safe for patients with Waldenstrom's macroglobulinemia. Some patients experienced mild to moderate side effects, such as bruising or diarrhea, but these were often temporary.

Mosunetuzumab and Pirtobrutinib are unique because they offer a novel approach to treating Waldenstrom's Macroglobulinemia, a rare type of non-Hodgkin lymphoma. While traditional treatments often involve chemotherapy and monoclonal antibodies like rituximab, these investigational drugs target the cancer more precisely. Mosunetuzumab is a bispecific antibody that directs the immune system to attack the cancer cells, while Pirtobrutinib is a highly selective BTK inhibitor that disrupts cancer cell signaling. Researchers are excited because this combination could provide a more effective and potentially less toxic treatment option by directly targeting the mechanisms that allow the cancer to thrive.

Research has shown that pirtobrutinib may help treat Waldenström's Macroglobulinemia. In the BRUIN study, pirtobrutinib reduced or eliminated tumors in 82.5% of patients, suggesting it could be a promising option for this condition.